Serum Interleukin 17 Levels in Patients with Crohn’s Disease: Real Life Data

Table 2

Disease features and medications of Crohn’s disease patients and assessment according to IL17 measurements.

	𝑛 (%)	IL17 (ng/L)	𝑃
Activity			>0.05
Active	20	23.82±11.12
Inactive	30	24.61±11.06
Behavior 𝑛 (%)			>0.05
Nonstricturing and nonpenetrating	29	24.07±11.11
Penetrating	18	24.40±11.94
Stricturing	3	25.83±6.26
Location			>0.05
Ileal	21	22.66±8.30
Ileocolonic	27	25.87±12.07
Colonic	2	30.50±22.45
Treatment groups			>0.05
Mesalazine group	16	24.56±11.72
Immunomodulatory group	22	23.62±10.39
Anti-TNF group	12	25.18±12.13
Immunomodulatory + anti-TNF	34	24.31±11.01